Indication: Lenvatinib, an anticancer medication recommended for use in order to treat patients with the locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
It is used together with the everolimus for treating patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
It is also recommended as the first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC).
How Lenvatinib works:
Lenvatinib blocks the function of proteins named RTKs (Receptor Tyrosine Kinases), involved in the formation of new blood vessels that help in order to supply the oxygen as well as nutrients to cells and help them to grow. These proteins can exist in high quantities in cancerous cells, and by blocking their function this medication may resist the rate at which the cancerous cells multiply and the tumour grows and help to cut off the blood supply needed for cancer.
Dosage of Lenvatinib:
Take Lenvima(Lenvatinib) once daily, with or without food, at the same time each day [see prescribing information for full dose schedule].
In a missed dose event, the dose must not be consumed within 12 hours, skip that specific dose and consume the upcoming dose at about the usual time of the administration.
Dose for Differentiated Thyroid Cancer (DTC): The recommended usual dose of Lenvatinib is 24 mg, should be consumed orally once daily until the disease progression or until the unacceptable toxicity.
Dose for Renal Cell Carcinoma (RCC): The recommended usual dose of Lenvatinib is 18 mg together with the 5 mg everolimus, should be consumed orally once daily until the disease progression or until the unacceptable toxicity.
Refer to the everolimus prescribing information for recommended dosing information about everolimus.
Dose for Hepatocellular Carcinoma (HCC): The recommended usual dose of Lenvatinib is based on the actual body weight:
Lenvatinib 12 mg for the patients who are greater than or equal to 60 kg or
Lenvatinib 8 mg for the patients who are less than 60 kg.
This drug must be consumed orally once daily until the disease progression or until the unacceptable toxicity.
Possible adverse reactions: Like all existing drugs, Lenvatinib can also be responsible for causing adverse reactions side effects, although not every individual gets them. The following adverse reactions may happen with this medication.
Most commonly reported adverse reaction may include:
Rash
High/Low blood pressure
Loss of appetite
Weight loss
Feeling sick
Constipation
Diarrhoea
Abdominal pain
Indigestion
Feeling very tired or weak
Hoarse voice
Swelling of the legs
Inflamed mouth
Hair loss
Trouble sleeping
Increased frequency in urination
Headache
Back pain
Weight gain, constipation
price: Lenvatinib price in India is economical, the only thing you need to keep in mind that you are choosing a legitimate pharmaceutical wholesaler while purchasing.
NOTE: The piece of information provided about "Indications and dosage of Lenvatinib" in this article is just for informational purposes and is not served as a substitute for the medical treatment, consultation, diagnosis, of a qualified healthcare practitioner.
Comments